Termination of Material Agreement Form 8 K

ITEM 1.02 - Termination of a Material Definitive Agreement.

As previously disclosed, on February 22, 2024, Insmed Incorporated (the "Company") entered into a Sales Agreement (the "Agreement") with Leerink Partners LLC, as agent ("Leerink"), under which the Company may offer and sell its common stock, par value $0.01 per share, from time to time having an aggregate offering price of up to $500,000,000 during the term of the Agreement through Leerink, acting as agent.

On November 18, 2024, the Company terminated the Agreement, which termination was immediately effective. Since September 30, 2024, no shares of common stock have been issued or sold pursuant to the Agreement. The Company is not subject to any termination penalties related to the termination of the Agreement. A copy of the Agreement was filed as Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the SEC on February 22, 2024 (the "Prior Form 8-K"). The foregoing summary of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, a copy of which is filed as Exhibit 10.1 to the Prior Form 8-K.